pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Trump administration cancels nearly $1 billion of congressional spending, targeting refugee and immigrant services

Sep 26, 2026·read at STAT ↗Negative

The White House announced on Friday that it is using a rarely invoked authority to rescind almost $1 billion in funding that Congress had approved earlier.

The cuts focus mainly on Health and Human Services programs that assist refugees and unaccompanied minors, which the administration says are no longer needed because border crossings have declined.

Additional reductions affect a Department of Education program for migrant students, a Justice Department office aimed at easing racial tensions, a minority business development initiative, HUD housing counseling, and several HHS grants described as “ideological”.

The move has been framed by the Office of Management and Budget as eliminating “the most harmful government spending,” but critics argue it undermines services for vulnerable populations.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Trump administration uses rare authority to claw back nearly $1B in spending approved by Congress”

read at STAT ↗
874 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.3
topics
Rare Disease3

related stories

  • Apr 28Opinion: Healthcare or health care? Help STAT decideSTAT
  • Apr 28Opinion: FDA commissioner: ‘Smarter,’ real-time clinical trials could transform drug developmentSTAT
  • Apr 28Pfizer deals extend patent life for a top-selling rare disease drugBioPharma Dive
  • Apr 28STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic accessSTAT
  • Apr 28Rocket's PRV goes for $180M; Oruka targets $500M offeringEndpoints